PepTivator® MAGE-A3 ( #130-095-384 #130-095-385 )

PepTivator® MAGE-A3

Description

PepTivator® MAGE-A3 is a pool of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap, covering the complete sequence of the human MAGE-A3 protein.
PepTivator peptide pools have been developed for the efficient in vitro stimulation of antigen–specific T cells, as peptides of 15 amino acids in length and 11 amino acids overlap represent an optimized solution for stimulating both CD4⁺ and CD8⁺ T cells in various applications.
Quantitative, phenotypical, or functional analysis of MAGE-A3–specific T cell immunity can provide important information on the natural course of immune responses.

Details

Background information
Melanoma-associated antigen 3 (MAGE-A3) belongs to the cancer testis family antigens. Expression is limited to male germ cells in normal tissue. It is aberrantly expressed in tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma, breast carcinoma, and hematological malignancies. MAGE-A3 was described to be an attractive antigen to monitor antitumor T cell responses and to be used for immunotherapeutic interventions.^1,2

Downstream applications
The in vitro stimulation of MAGE-A3–specific CD4⁺ and CD8⁺ T cells with PepTivator MAGE-A3 causes the secretion of effector cytokines and the up-regulation of activation markers, such as CD154 or CD137. These cytokines or activation markers then allow the detection and isolation of MAGE-A3–specific T cells.

Detection and analysis of MAGE-A3–specific CD4⁺ and CD8⁺ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
Isolation of viable MAGE-A3–specific CD4⁺ T cells with the CD154 MicroBead Kit, or of CD4⁺ and CD8⁺ T cells using the CD137 MicroBead Kit or MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
Generation of MAGE-A3–specific CD4⁺ and CD8⁺ effector/memory T cells from naive T cell populations for research on immunotherapy and vaccination.
Pulsing of antigen-presenting cells for research on dendritic cell vaccination.